
Events Search and Views Navigation
April 2019
Intelligent Automation for Life Sciences (IA in Pharma)
Location: Boston, MA With life sciences companies spending over a billion dollars in R&D for one potential new drug, medical devices or medical supply product, the use of IA technologies have the potential to reap savings across the entire commercialization process from discovery to clinical trials to commercialization and marketing. NOW is the time to take action and the best way to do so is to learn more about how to successful launch, implement, and/or expand IA programs on a…
Find out more »June 2019
iPharma 2019
Location: Baltimore, MD iPharma 2019 includes nearly every permutation of knowledge, innovation, technology and networking; and has an objective of creating an international forum for academicians, practitioners and business professionals to discuss the soundest issues related to Pharma, Biotech and Health Care. This program provides three days of robust discussions in the field of Drug Discovery and Development, Pharmacovigilance and Drug Safety, Novel Drug Delivery Systems and Drug therapy, Pharmaceutical Nanotechnology, Drug Regulatory Affairs, Pharmacology, Neuropharmacology, Nutraceuticals, Pharma Marketing, Orphan…
Find out more »November 2019
ai Innovations for Life Sciences and Health Care Summit – WEST
Location: San Francisco, CA Artificial intelligence is being used by life science organizations to accelerate drug development and spur medical device innovation through genomic profiling, and optimize clinical development strategies. Machine learning and model training have the ability to efficiently analyze large volumes of data for deeper insights to inform novel therapy development. While systems and platforms have been developed to transform several stages of the therapeutic development life cycle, the industry is becoming more demanding of real-world examples of…
Find out more »May 2022
Reuters Events: Pharma Clinical 2022
Location: virtual The pandemic response has accelerated technology adoption in clinical trials, but we have neglected patient needs by failing to develop co-created, data-driven, standardised and accountable trial designs. In the face of rethinking clinical strategy, our mission is clear: it’s time to develop a better system. We must establish new industry-wide benchmarks now, leverage recent digital innovations, and ensure permanent cultural change toward patient- centric trials. If we do not act immediately, we risk losing this opportunity to rebuild…
Find out more »